A Pharmacokinetic Sub-Study of QUILT-3.032 (CA ALT-803-01-16): A Multicenter Clinical Trial of Intravesical Bacillus Calmette-Guerin (BCG) in Combination With ALT-803 in Patients With BCG Unresponsive High Grade Non-Muscle Invasive Bladder Cancer and QUILT-2.005: A Study of Intravesical BCG in Combination With ALT-803 in Patients With Non-Muscle Invasive Bladder Cancer
Latest Information Update: 12 Dec 2024
At a glance
- Drugs Nogapendekin alfa inbakicept (Primary) ; BCG
- Indications Bladder cancer; Carcinoma
- Focus Pharmacokinetics
- Sponsors Altor BioScience Corporation
Most Recent Events
- 20 Jan 2021 Status changed from recruiting to discontinued due to the recent pandemic and enrollment challenges.
- 07 Apr 2020 Protocol of trial has been amended to include sub-study of QUILT-2.005 and treatment cohort increased from 2 to 3.
- 04 Nov 2019 New trial record